Kyle Kline
CIK 2080625 · View on SEC EDGAR ↗
First SEC filing: Aug. 27, 2025 · Latest: Aug. 27, 2025
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 8, 2026 | GMED | S 10b5-1 | 3,594 | $101.10 | $363,353 | 0 Direct | -100.00% | Disposed | -12.7% (price as of 2026-08-19) |
| Dec. 1, 2025 | GMED | S 10b5-1 | 18,542 | $90.00 | $1,668,780 | 0 Direct | -100.00% | Disposed | -2.0% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 21, 2026 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (30,000) | $94.15 | Jan. 21, 2036 | 30,000 | Acquired |
| Jan. 8, 2026 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (3,594) | $51.87 | March 14, 2034 | 3,594 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (4,896) | $63.68 | Jan. 27, 2032 | 4,896 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (5,000) | $63.68 | Jan. 27, 2032 | 5,000 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (5,000) | $64.44 | Jan. 25, 2031 | 5,000 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (5,000) | $56.43 | Feb. 27, 2034 | 5,000 | Disposed |
| Dec. 1, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (3,646) | $53.14 | March 24, 2033 | 3,646 | Disposed |
| July 18, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (20,909) | $56.34 | July 18, 2035 | 20,909 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 7 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (5,000) | 5,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (5,000) | 5,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (5,000) | 5,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (5,000) | 5,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (15,000) | 15,000 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (7,500) | 7,500 | Direct |
| Aug. 27, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (9,091) | 9,091 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
GMED
CFO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $334,040 | $50,000 | — | — | $200,000 | — | $33,264 | $1,380,258 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.